NICE-aligned management typically involves: Addressing modifiable risk factors (smoking cessation, weight loss, increased physical activity, alcohol reduction) Optimising management of underlying conditions (diabetes, hypertension, depression) Trial of PDE5 inhibitor therapy Referral to specialist services (urology/andrology) if first-line treatments fail or where structural/neurological/endocrine causes are suspected Consideration of psychosexual therapy where appropriate Men should be reassured that ED is a medical condition with effective treatments, and seeking help through proper channels ensures safety, appropriate investigation of underlying causes, and access to evidence-based therapies
Research Benefits (Observed in Studies)
This sequence is what gives it its unique properties and function
Friedman does not directly dispense these compounds
Subjects in studies of six individual peptides growth hormone releasing peptide-2, ibutamoren mesylate, ipamorelin, CJC-1295, AOD-9604 and melanotan II experienced adverse events, including death